Company profile: Audentes Therapeutics
1.1 - Company Overview
Company description
- Provider of gene therapy research and development for rare muscle diseases, serving as the Gene Therapy Center of Excellence with divisions in technical operations, medical and development, and future commercialization of gene therapy programs.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Audentes Therapeutics
AMO Pharma
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical drug candidates targeting rare muscular and central nervous system disorders, including AMO-02 (tideglusib) for congenital myotonic dystrophy, AMO-01 inhibiting the Ras-ERK pathway for Phelan-McDermid Syndrome, and AMO-04, a glutamate modulator, for Rett syndrome and certain breathing disorders; advancing clinical-stage assets and expanding the pipeline via acquisitions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AMO Pharma company profile →
Aceragen
HQ: United States
Website
- Description: Provider of therapeutic treatments for rare and ultra-rare diseases, developing investigational products including ACG-801, a recombinant human acid ceramidase enzyme replacement therapy for Farber disease, and ACG-701, an oral sodium fusidate antibiotic for melioidosis and for acute pulmonary exacerbations in cystic fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aceragen company profile →
AesRx
HQ: United States
Website
- Description: Provider of biopharmaceutical drug development focused on orphan diseases, developing two novel candidates, Aes-103 and Aes-210. Lead program Aes-103 is a potential breakthrough for treating sickle cell disease, a recessive hemoglobin disorder that can cause red blood cells to deform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AesRx company profile →
Quellis Bio
HQ: United States
Website
- Description: Provider of next-generation antibody therapies aimed at improving outcomes for patients with serious rare diseases, focusing on discovering best-in-class new molecules to address underserved treatment needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quellis Bio company profile →
Cydan
HQ: United States
Website
- Description: Provider of orphan drug accelerator services focused on identifying and de-risking compounds with therapeutic and commercial potential.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cydan company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Audentes Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Audentes Therapeutics
2.2 - Growth funds investing in similar companies to Audentes Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Audentes Therapeutics
4.2 - Public trading comparable groups for Audentes Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →